UK startup Leucid raises £11.5m for solid tumour CAR-T therapiesCAR-T therapies have revolutionised the treatment of some blood cancers, but so far haven’t been able to repeat Share XUK startup Leucid raises £11.5m for solid tumour CAR-T therapieshttps://pharmaphorum.com/news/uk-startup-leucid-raises-11-5m-for-solid-tumour-car-t-therapies/
Shaping the future of ovarian cancer diagnosis with femtechIsraeli femtech start-up GinaLife is developing a platform of biomarker strategies supported by artificial intelligence and data science Share XShaping the future of ovarian cancer diagnosis with femtechhttps://pharmaphorum.com/digital/ginalife-ovarian-cancer-diagnosis-femtech/
NICE backs ovarian cancer and multiple myeloma combination drugsNICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma. In final draft Share XNICE backs ovarian cancer and multiple myeloma combination drugshttps://pharmaphorum.com/news/nice-backs-ovarian-cancer-and-multiple-myeloma-combination-drugs/
EU regulators back uses for AZ’s Lynparza in prostate and ovarian cancerAstraZeneca may have had a rough ride following a safety scare with its COVID-19 vaccine, but the company’s Share XEU regulators back uses for AZ’s Lynparza in prostate and ovarian cancerhttps://pharmaphorum.com/news/az-grabs-twin-eu-approval-for-lynparza-in-prostate-and-ovarian-cancer-uses/
Roche’s Tecentriq cocktail fails in newly-diagnosed ovarian cancerA cocktail of drugs including Roche’s Tecentriq has failed to improve progression-free survival in ovarian cancer patients, before or after surgery. Roche had Share XRoche’s Tecentriq cocktail fails in newly-diagnosed ovarian cancerhttps://pharmaphorum.com/news/roches-tecentriq-cocktail-fails-in-newly-diagnosed-ovarian-cancer/
AZ/Merck & Co’s Lynparza sets ‘new standards’ in ovarian cancerAstraZeneca and Merck & Co’s Lynparza should be the standard therapy for a certain group of ovarian cancer patients according to US Share XAZ/Merck & Co’s Lynparza sets ‘new standards’ in ovarian cancerhttps://pharmaphorum.com/news/azs-lynparza-sets-new-standards-in-ovarian-cancer-say-experts/
AZ/Merck & Co’s ovarian cancer drug gets wider US licenceAstraZeneca and Merck & Co have hit back at their rival GlaxoSmithKline after the FDA allowed Lynparza to Share XAZ/Merck & Co’s ovarian cancer drug gets wider US licencehttps://pharmaphorum.com/news/az-merck-co-ovarian-cancer-drug-gets-wider-us-licence/
GSK takes fight to AZ/Merck & Co with first-line ovarian cancer approvalThe FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against Share XGSK takes fight to AZ/Merck & Co with first-line ovarian cancer approvalhttps://pharmaphorum.com/news/fda-approves-gsks-zejula/
Epsilogen licenses first-in-class IgE ovarian cancer drugUK biotech Epsilogen has licensed rights to a drug for solid tumours developed by Kings College London and Share XEpsilogen licenses first-in-class IgE ovarian cancer drughttps://pharmaphorum.com/news/epsilogen-licenses-first-in-class-ige-ovarian-cancer-drug/
